Sterling Pharma Solutions, a CDMO,  is investing £6m into its pilot plant facility at its UK site to enhance its scale-up and small to midscale commercial API manufacturing capabilities.   The expansion will increase the pilot plant’s capacity by 33% and enhance the site’s production capabilities and flexibility for small to mid-scale batch production. Three new reactor trains will be added at scales of 225L, 500L and 1,360L to the cGMP facility. This will help to meet growing market dem...